Verdeca Introduces HB4® Drought Tolerant Soybeans to Growers at Argentina’s Expoagro
— Highly favorable response to pre-commercial introduction of HB4 technology —
DAVIS, Calif. and ROSARIO, Argentina (March 26, 2019) – Verdeca, a joint venture between Arcadia Biosciences, Inc. (Nasdaq: RKDA) and Bioceres Crop Solutions Corp. (NYSE American: BIOX), introduced pre-commercial soybean varieties carrying the drought-tolerant HB4® trait to growers in Argentina at the country’s largest farm show, Expoagro, held March 12th to 15th in San Nicolas, Argentina. The soybean varieties deliver two layers of value for growers: drought and herbicide tolerance.
The HB4 trait is Verdeca’s first release from a pipeline of yield and quality traits and demonstrates the company’s ability to bring innovation to soybean growers. The result of years of R&D, HB4 soybean varieties reduce yield loss when the crop is challenged by drought.
More than 1,200 attendees toured the Verdeca pavilion and field plots to see HB4 soybeans. Growers visiting the Verdeca pavilion signed on to the company’s Bio-Innovator program, which grants priority access to test HB4 soybean varieties in their fields.
“After the worst drought of the last 50 years, soybean growers are keenly aware of the difficulties in maintaining high yields in the face of climate uncertainty,” said Martin Mariani Ventura, general manager of Verdeca. “Our field trials in the drought-stricken areas of Argentina showed HB4 soybeans can significantly preserve yield compared with non-HB4 soybean varieties.”
In addition to drought tolerance, HB4 soybeans also offer resistance to glufosinate, a broad-spectrum herbicide used to control a wide range of weeds. Field plots at Expoagro demonstrated the effectiveness of the trait plus herbicide combination to control weeds in plots artificially infested with Amaranthus sp., volunteer corn and other grasses.
“Farmers have responded favorably to the pre-commercial introduction of our HB4 technology, reinforcing the market demand and potential for climate resilient crops,” said Raj Ketkar, president and CEO of Arcadia Biosciences. “HB4 trait technology is currently being bred into elite soybean varieties by Verdeca’s seed company partners, and we are preparing for the commercial launch of HB4 in 2019, pending regulatory approval in China.”
Arcadia and Bioceres formed Verdeca in 2012 to deploy next-generation soybean traits across all key production regions, beginning in South America and North America, which together represent nearly 80 percent of the harvested soybean acres globally. Verdeca’s HB4 trait has already been approved in Argentina and by the U.S. Food & Drug Administration. Regulatory submissions are currently under consideration by the U.S. Department of Agriculture and in Brazil, Paraguay, Uruguay, Bolivia and China.
Verdeca, a U.S.-based joint venture between Bioceres Crop Solutions Corp. and Arcadia Biosciences, develops and deregulates soybean varieties with next-generation agricultural technologies. Working in partnership with South American growers, Verdeca aims to provide technologies that help increase crop productivity, making more efficient and sustainable use of land and water resources. For more information visit www.verdeca.com.
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company’s agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. For more information, visit www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s and its par tners’ and affiliates’ ability to develop commercial products incorporating their traits, and complete the regulatory review process for such products; Arcadia’s compliance with laws and regulations that impact Arcadia’s business, and changes to such laws and regulations; Arcadia’s future capital requirements and ability to satisfy its capital needs; and the other risks set forth in Arcadia’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2017 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
Contact: Arcadia Biosciences